CompletedPhase 1NCT04811196
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
Studying Endometrial stromal sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Health Network, Toronto
- Principal Investigator
- Albiruni Razak, M.D., STNAPrincess Margaret Cancer Centre
- Intervention
- Selinexor(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04811196 on ClinicalTrials.govOther trials for Endometrial stromal sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07467772Ph 2 Elacestrant in ER Positive Uterine SarcomasDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT03624244Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)Centre Leon Berard
- RECRUITINGNCT00005095Specimen and Data Study for Ovarian Cancer Early Detection and PreventionNorthwestern University